Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Plus therapeutics, inc. save search
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 2.96%
H: 0.57%
C: -7.47%
trial therapeutics plus
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
Published: 2023-11-20 (Crawled : 12:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -15.59%
H: 12.61%
C: -14.41%
meeting trial therapeutics plus
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 6.39%
H: 0.0%
C: -1.26%
trial therapeutics plus
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -1.07%
H: 2.17%
C: -1.44%
trial therapeutics plus
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
Published: 2023-08-11 (Crawled : 11:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 5.33%
H: 0.0%
C: -20.89%
conference cancer trial therapeutics plus
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
Published: 2023-08-08 (Crawled : 15:20) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 1.53%
H: 8.3%
C: -0.38%
conference cancer trial therapeutics plus
Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-04-19 (Crawled : 12:20) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -1.14%
H: 22.39%
C: 4.39%
trial therapeutics plus
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases
Published: 2023-04-18 (Crawled : 12:20) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -0.11%
H: 5.28%
C: 3.8%
trial therapeutics plus
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-03-28 (Crawled : 12:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: -2.68%
trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
trial therapeutics plus phase 1
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 3.23%
H: 0.0%
C: -6.25%
treatment trial therapeutics plus phase 2b glioblastoma
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
Published: 2022-10-19 (Crawled : 11:00) - globenewswire.com
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: -2.44%
nuclear trial therapeutics plus
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 1.48%
H: 22.86%
C: 8.56%
trial therapeutics plus
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -1.37%
H: 6.87%
C: -0.54%
BIOC | $0.4349 -10.32% 750K
|
Health Services
|
| O: -1.41%
H: 4.76%
C: -5.71%
services trial therapeutics plus agreement
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
Published: 2022-06-16 (Crawled : 13:20) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 4.23%
H: 2.88%
C: -0.69%
trial therapeutics plus phase 1
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 6.82%
H: 0.0%
C: -5.77%
trial imaging therapeutics plus positive molecular
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
Published: 2022-03-22 (Crawled : 12:30) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -0.99%
H: 10.0%
C: 0.0%
trial therapeutics phase 1
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial
Published: 2022-02-22 (Crawled : 19:00) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: -4.9%
H: 13.4%
C: 4.12%
control brain cancer trial therapeutics cel cancer train
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
PSTV | $1.74 3.8K
|
Health Technology
|
| O: 1.2%
H: 11.31%
C: -5.36%
phase 1 positive trial
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.